TB-500 (Ac-LKKTETQ) (TB-500)
Thymosin Beta-4 Active Fragment | Healing Peptide
Community Research
Join others researching TB-500 (Ac-LKKTETQ) — share findings, ask questions, and learn from real experiences
TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.
TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration. It promotes angiogenesis by upregulating VEGF expression and enhancing endothelial cell sprouting. The peptide undergoes serial cleavage at the C-terminus during metabolism, while the N-terminal acetylation provides protection from degradation.
Molecular Data
?LKKTETQAc
Position 1
Leucine
Position 2
Lysine
Position 3
Lysine
Position 4
Threonine
Position 5
Glutamic Acid
Position 6
Threonine
Position 7
Glutamine
Position 8
Research Indications
Promotes dermal wound healing through the active LKKTETQ sequence.
Supports tissue repair comparable to full thymosin beta-4 in research.
Promotes keratinocyte migration and collagen deposition.
Promotes endothelial cell differentiation and new blood vessel formation.
Decreases inflammatory responses in damaged tissues.
Dosing Protocols
TB-500 is typically administered via subcutaneous injection. The N-terminal acetylation provides stability and protection from degradation. Not authorized for medicinal use; research peptide only.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Loading phase | 2-2.5 mg | 2x weekly for 4-6 weeks | SubQ |
| Maintenance | 2 mg | Weekly or bi-weekly | SubQ |
Reconstitution Instructions
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs
- Peptide vial
- Sterile work surface
- 1 Clean work area and hands thoroughly
- 2 Calculate required BAC water volume
- 3 Draw BAC water into syringe
- 4 Inject slowly down vial side
- 5 Gently swirl until dissolved (never shake)
- 6 Store reconstituted solution refrigerated
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Injection site reactions
- Mild fatigue
- Head rush (reported)
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual swelling or inflammation
Contraindications
- Not authorized for medicinal use
- Active cancer (theoretical concern)
- Pregnancy or breastfeeding
- Prohibited by WADA in sports
Quality Checklist
Good Signs
- White lyophilized powder
- Clear solution after reconstitution
- High purity (>98%)
- Intact vacuum seal
Warning Signs
- Not authorized for human use
- Research chemical only
Bad Signs
- Discoloration
- Cloudy solution
- Particulates visible
References
- Synthesis and Characterization of N-terminal Acetylated 17-23 Fragment of Thymosin Beta-4Drug Testing and Analysis (2012)
TB-500 contains Ac-LKKTETQ, the active site responsible for actin binding and wound healing.
- Doping Control Analysis of TB-500Journal of Chromatography B (2012)
TB-500 is a synthetic version of the active region of thymosin beta-4.
- TB-500 Metabolism and Wound HealingJournal of Chromatography B (2024)
TB-500 undergoes serial cleavage at C-terminus; acetylation protects N-terminus.
- Investigation of TB-500 MetabolismWADA (2018)
Characterized human metabolism of TB-500 using liver microsomes and S9 fraction.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.